• Formononetin Mitigates Oxaliplatin Neurotoxicity via Nrf2/HO

  2026-07-27

  This study demonstrates that formononetin protects sensory neurons from oxaliplatin-induced peripheral neurotoxicity by activating the Nrf2/HO-1 antioxidant pathway. Importantly, it preserves the chemotherapeutic efficacy of oxaliplatin, addressing a central challenge in chemotherapy support strategies.

• Deracoxib: Selective COX-2 Inhibitor for Advanced Inflammati

  2026-07-26

  Deracoxib stands out as a selective COX-2 inhibitor with unique dual benefits: robust anti-inflammatory and antitumor properties, plus proven synergy with doxorubicin to protect normal cells. Researchers leveraging APExBIO’s Deracoxib unlock optimized workflows for canine pain, inflammation, and cancer models, supported by actionable protocol guidance and troubleshooting insights.

• Affinity-Purified Goat Anti-Rabbit IgG (H+L) for Robust Sign

  2026-07-25

  The Affinity-Purified Goat Anti-Rabbit IgG (H+L) antibody, HRP-conjugated, transforms protein detection in immunoassays by maximizing sensitivity and specificity. Discover optimized workflows, real-world troubleshooting, and unique insights into inflammation research as enabled by this high-performance secondary antibody.

• PRINT: RNA-Mediated Site-Specific Transgene Insertion in Hum

  2026-07-24

  The reference study introduces PRINT, an RNA-only method for precise, safe-harbor transgene insertion in human cells using engineered retroelement proteins. This platform demonstrates high efficiency and minimizes genome disruption, providing a significant advance for gene therapy and genome engineering workflows.

• Lyso-Tracker Red: Advancing Live-Cell Lysosome Labeling Work

  2026-07-24

  Lyso-Tracker Red, supplied by APExBIO, delivers unmatched specificity and reliability for lysosome labeling in live cells, empowering researchers to dissect lysosomal dynamics in health and disease. From advanced cancer studies to troubleshooting live-cell imaging, this guide translates cutting-edge research into actionable protocols and optimization insights.

• Ceruletide (SKU B8465): Reliable Modeling in Pancreatic Rese

  2026-07-23

  This authoritative article explores how Ceruletide (SKU B8465) from APExBIO drives reproducible, high-sensitivity modeling in pancreatic and gastrointestinal function research. Scenario-driven Q&A blocks address real laboratory challenges—ranging from assay reproducibility to product selection—grounded in peer-reviewed evidence and best practices. Researchers will find actionable guidance and protocol parameters to ensure robust, data-backed results with Ceruletide.

• Acetylspiramycin (Spiramycin B) in Reliable Antimicrobial As

  2026-07-23

  This article provides scenario-driven guidance for researchers using Acetylspiramycin (Spiramycin B), SKU BA1075, to address real-world challenges in antimicrobial resistance research, cell-based workflows, and protocol reproducibility. Drawing on recent literature and validated product data, it demonstrates how BA1075 offers robust, sensitive, and reproducible solutions for microbiological and immunomodulation assays.

• Oligo (dT) 25 Beads: Optimizing Eukaryotic mRNA Isolation Wo

  2026-07-22

  Oligo (dT) 25 Beads from APExBIO offer high-yield, rapid, and scalable magnetic mRNA purification, crucial for advanced transcriptomics and multiomics studies in animal and plant research. This guide details optimized protocols, troubleshooting tactics, and practical insights, translating leading multiomics research into actionable laboratory strategies.

• Anti-Diabetic Drugs and Fracture Risk: Systematic Review Ins

  2026-07-22

  This systematic review and network meta-analysis comprehensively evaluated the impact of anti-diabetic drugs—including SGLT2 inhibitors such as Ertugliflozin—on fracture risk in type 2 diabetes patients. The findings clarify differential risks among drug classes and highlight the complexity of balancing glycemic control with skeletal safety in diabetes management.

• VX-745: Potent, Selective p38α MAPK Inhibitor for Research

  2026-07-21

  VX-745 is a highly selective p38α MAPK inhibitor with nanomolar potency, blocking key inflammatory pathways and cytokine secretion. Its dual-action mechanism, verified by recent structural and cellular studies, positions it as a powerful tool for inflammation and disease modeling.

• Latrunculin B (C5804): Reliable Actin Dynamics for Cell Assa

  2026-07-21

  This article provides laboratory scientists with authoritative, scenario-driven guidance on leveraging Latrunculin B (SKU C5804) for reproducible actin cytoskeleton disruption in cell viability and cytotoxicity assays. We address experimental design pitfalls, protocol optimization, and vendor reliability—grounded in peer-reviewed evidence—for superior workflow outcomes.

• LncRNA FAISL Regulates Calpain 2–FAK Axis in TNBC Progressio

  2026-07-20

  This study elucidates a novel mechanism in triple negative breast cancer (TNBC) involving the lncRNA FAISL, which stabilizes FAK protein by inhibiting its calpain 2-mediated proteolysis. These findings advance understanding of focal adhesion dynamics, with implications for targeting FAISL and calpain-FAK signaling in aggressive breast cancer.

• Distinct Roles of GluN2A/2B in Trigeminal Ganglion Sensitiza

  2026-07-20

  This study uncovers how N-methyl-D-aspartate receptor (NMDAR) subunits GluN2A and GluN2B distinctly regulate connexins and pannexins in the trigeminal ganglion, driving orofacial inflammatory allodynia during temporomandibular joint inflammation. The findings clarify molecular pathways underlying pain sensitization and highlight new targets for translational pain research.

• Tirbanibulin Analogs Inhibit BoNT/A SNAP-25 Cleavage in Neur

  2026-07-19

  This study demonstrates that KX2-391 (Tirbanibulin dihydrochloride) and its analog KX2-361 can inhibit botulinum neurotoxin A (BoNT/A)–mediated SNAP-25 cleavage in neuronal models, including both pre- and post-intoxication settings. The findings highlight a promising avenue for small-molecule interventions targeting intracellular BoNT/A, a critical step toward developing therapeutics for botulism cases where current antibody-based therapies are ineffective.

• Distinct Roles of GluN2A/B in Trigeminal Allodynia During TM

  2026-07-18

  This study uncovers how NMDA receptor subunits GluN2A and GluN2B distinctly regulate connexins and pannexins in the trigeminal ganglion during orofacial inflammatory allodynia arising from TMJ inflammation. These insights reveal new molecular targets for peripheral sensitization and pain management in temporomandibular joint disorders.

451 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page